Krystal Biotech (FRA:4KB) ROCE % : 2.93% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Krystal Biotech ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Krystal Biotech's annualized ROCE % for the quarter that ended in Mar. 2024 was 2.93%.

Krystal Biotech ROCE % Historical Data

The historical data trend for Krystal Biotech's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Krystal Biotech ROCE % Chart

Krystal Biotech Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-13.95

-12.36

-15.56

-25.62

1.94

Krystal Biotech Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-28.16	-26.18	-14.72	57.91	2.93

Krystal Biotech ROCE % Calculation

Krystal Biotech's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	11.827	/	( ( (527.177 - 27.232)	+	(750.432 - 30.347) )	/ 2 )
	=	11.827	/	( (499.945	+	720.085)	/ 2 )
	=	11.827	/	610.015
	=	1.94 %

Krystal Biotech's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	21.404	/	( ( (750.432 - 30.347)	+	(785.032 - 43.782) )	/ 2 )
	=	21.404	/	( ( 720.085	+	741.25 )	/ 2 )
	=	21.404	/	730.6675
	=	2.93 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Krystal Biotech (FRA:4KB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Krystal Biotech ROCE % Related Terms

Thank you for viewing the detailed overview of Krystal Biotech's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Krystal Biotech (FRA:4KB) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Krystal Biotech Inc (FRA:4KB) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

KRYS:USA 4KB:Germany

Address

2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203

Website

https://www.krystalbio.com

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on development of easy to use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future.

Krystal Biotech (FRA:4KB) Headlines

No Headlines